Based on the KalVista Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for KalVista Pharmaceuticals Inc is not available over the next 12 months. KalVista Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of KalVista Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, KalVista Pharmaceuticals Inc’s stock price was EUR 8.50. KalVista Pharmaceuticals Inc’s stock price has changed by -2.30% over the past week, -16.67% over the past month and +4.94% over the last year.
No recent analyst target price found for KalVista Pharmaceuticals Inc
No recent average analyst rating found for KalVista Pharmaceuticals Inc
Company Overview KalVista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts. Read Less
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein in...Read More
Frequently Asked Questions About KalVista Pharmaceuticals Inc (4XC1:F) Stock
Stock Target Advisor's fundamental analysis for KalVista Pharmaceuticals Inc's stock is Very Bearish.
Unfortunately we do not have enough data on 4XC1:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4XC1:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 4XC1:F's stock to indicate if its overvalued.
The last closing price of 4XC1:F's stock was EUR 8.50.
The most recent market capitalization for 4XC1:F is EUR 0.45B.
Unfortunately we do not have enough analyst data on 4XC1:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains KalVista Pharmaceuticals Inc's stock.
As per our most recent records KalVista Pharmaceuticals Inc has 150 Employees.
KalVista Pharmaceuticals Inc's registered address is 55 Cambridge Parkway, Cambridge, MA, United States, 02142.
You can get more information about it from KalVista Pharmaceuticals Inc's website at https://www.kalvista.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About KalVista Pharmaceuticals Inc (4XC1:F) Stock
Stock Target Advisor's fundamental analysis for KalVista Pharmaceuticals Inc's stock is Very Bearish.
Unfortunately we do not have enough data on 4XC1:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4XC1:F's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on 4XC1:F's stock to indicate if its overvalued.
The last closing price of 4XC1:F's stock was EUR 8.50.
The most recent market capitalization for 4XC1:F is EUR 0.45B.
Unfortunately we do not have enough analyst data on 4XC1:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains KalVista Pharmaceuticals Inc's stock.
As per our most recent records KalVista Pharmaceuticals Inc has 150 Employees.
KalVista Pharmaceuticals Inc's registered address is 55 Cambridge Parkway, Cambridge, MA, United States, 02142.
You can get more information about it from KalVista Pharmaceuticals Inc's website at https://www.kalvista.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4XC1:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
